7.75 +0.05 (0.65%)
After hours: 6:12PM EDT
|Bid||7.72 x 1800|
|Ask||7.70 x 900|
|Day's range||7.62 - 8.40|
|52-week range||2.43 - 46.67|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Tilray, Inc.'s (NASDAQ:TLRY): Tilray, Inc. engages in the research, cultivation, processing, and distribution of...
Investors need to pay close attention to Tilray (TLRY) stock based on the movements in the options market lately.
The best defense during a market downturn is usually a good offense. Here are two high-growing cannabis companies that are likely to continue their momentum.
Today, we'll look at which of the two leading companies in the marijuana sector, Aphria (NASDAQ: APHA) and Tilray (NASDAQ: TLRY), is a better buy right now. During the first quarter of 2020, Tilray recognized $52.1 million in revenue, a rise of 126% year over year. Although that growth is spectacular, the company is not profitable -- it recorded a net loss of $184 million, largely due to non-cash adjustments to the fair value of its warrants.
If you think the stock market has had a wild go of things lately, take a gander at marijuana stocks over the past three years. Until the end of the first quarter of 2019, pot stocks were virtually unstoppable. It was not uncommon for cannabis stocks to have delivered triple-digit or quadruple-digit gains to their shareholders.
Despite recent troubles, Canopy Growth is optimistic its cannabis beverages can dwarf the growth of hard seltzers.
Shares of Canopy growth (CGC) are trading 30% lower since its latest quarterly results last week. However one analyst sees share as undervalued for the Canadian cannabis company which has shifted from medical to more recreational sales when that market was legalized in Canada almost two years ago. “Although we expect the medical market to shrink because of recreational legalization, we forecast more than 10% average annual growth for the entire Canadian market through 2030, driven by the conversion of black-market consumers into the legal market and new cannabis consumers,” analyst Kristoffer Inton wrote in a note to investors.
A pair of marijuana stocks, Tilray (NASDAQ: TLRY) and OrganiGram Holdings (NASDAQ: OGI), both dropped notably in price on Friday (by 5.2% and 7%, respectively). The culprit seems to be another weed title, Canopy Growth (NYSE: CGC), which earlier in the day published an awful quarterly earnings release. Canopy Growth is a leading company in the sector.
Canadian cannabis company Tilray's (NASDAQ: TLRY) CEO believes that at least 12 marijuana companies will go under this year. In March, Tilray announced that it would be raising $90.4 million through an offering, largely because the company still could. CEO Brendan Kennedy told BNN Bloomberg that he "wasn't sure anyone was going to be able to raise any money in this industry again" and that "when we had the opportunity to strengthen the balance sheet, we did."
Ladies and gentlemen, thank you for standing by, and welcome to Tilray's First Quarter 2020 Earnings Conference Call. Good afternoon, and thank you for joining us on Tilray's first quarter 2020 earnings conference call and webcast. On with me today are Brendan Kennedy, Chief Executive Officer; and Michael Kruteck, Chief Financial Officer.
Tilray's (NASDAQ:TLRY) 55% year-to-date loss is, without question, really bad. But it could have been much worse. Actually, it was much worse. At one point in March, Tilray had plunged nearly 90%.
Tilray Inc (TLRY) delivered earnings and revenue surprises of -11.36% and 4.85%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
What happened Tilray (NASDAQ: TIL) shareholders outperformed a strong market last month. The stock rose 17% compared to a 13% increase in the S&P 500, according to data provided by S&P Global Market Intelligence.
Investors are “anxious” about the markets, but “aggressive’’ about investment opportunities, Caleb Silver, editor-in-chief of Investopedia, told Yahoo Finance.